Development and maturation of norovirus antibodies in childhood

Show full item record



Permalink

http://hdl.handle.net/10138/217892

Citation

Blazevic , V , Malm , M , Honkanen , H , Knip , M , Hyoty , H & Vesikari , T 2016 , ' Development and maturation of norovirus antibodies in childhood ' Microbes and Infection , vol. 18 , no. 4 , pp. 263-269 . DOI: 10.1016/j.micinf.2015.12.004

Title: Development and maturation of norovirus antibodies in childhood
Author: Blazevic, Vesna; Malm, Maria; Honkanen, Hanna; Knip, Mikael; Hyoty, Heikki; Vesikari, Timo
Contributor: University of Helsinki, Children's Hospital
Date: 2016-04
Language: eng
Number of pages: 7
Belongs to series: Microbes and Infection
ISSN: 1286-4579
URI: http://hdl.handle.net/10138/217892
Abstract: The burden of norovirus (NoV) gastroenteritis is substantial in young children. Maternal antibodies are thought to protect a child from NoV infection in early infancy but subsequent development of NoV-specific protective immunity in children is still largely unexplored. We have determined NoV-specific antibody seroconversion to GII.4 virus-like particles as an indicator of NoV infection in two children prospectively followed from birth to eight years of age. Blocking activity and affinity maturation of maternal and serum IgG antibodies were evaluated. Our results show that multiple infections occur in children up to eight years of age. The titer, blocking activity and avidity of maternal antibodies determined susceptibility of an infant to NoV infection. NoV GII.4-specific antibodies with high blocking potential and avidity were developed at two to three years of age and were retained throughout the follow-up. Subsequent NoV infections may have contributed to the duration of protective NoV-specific immune responses that lasted for several years. This study adds to current understanding of the duration of passive protection by maternal antibodies and the duration and quality of acquired immunity following primary and subsequent NoV infections in infants and young children, who are the main target group for NoV vaccine development. (C) 2016 The Authors. Published by Elsevier Masson SAS on behalf of Institut Pasteur.
Subject: Norovirus
Infant
Children
Immunity
Infections
Serology
VIRUS-LIKE PARTICLES
BLOOD GROUP ANTIGENS
ACUTE GASTROENTERITIS
IMMUNE-RESPONSES
UNITED-STATES
BLOCKING ANTIBODIES
VACCINE DEVELOPMENT
FINNISH CHILDREN
BIRTH COHORT
INFECTION
3121 Internal medicine
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1286457915002634_main.pdf 488.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record